1. Home /
  2. Biotechnology


Incyte Gets a Quantitative Upgrade

We have two price target areas for this biopharmaceutical firm.

Why Are Insiders Buying These 2 Stocks?

An oncology and a oil & gas concern, new names on my list, have my attention.

As Celldex Recovers, Here's My Strategy

Let's check the charts on this clinical stage drug developer.

2 Momentum Trades Showing Worst to First Action

These names are off to good starts to 2023 and could have more room to run.

Moderna Shares Surge on Promising Vaccine Results

Let's check the charts and indicators.

3 Potential Biotech Buyout Targets

There are signs that M&A deal activity will pick up in the sector after a couple of subpar years.

Could These Biotechs Be the Top Performers in 2023?

Industry experts share their favorite biotech plays for this year.

Rain Oncology Could See Sunny Days Ahead

The oncology company's stock has been correcting sideways for a few months but seems poised for renewed gains.

Expect Biotech to Head Higher in 2023

Let's dip into the biotech mailbag as the year comes to an end.

Beam Therapeutics Needs More Bottoming Price Action

Here's what traders should wait for.